---
document_datetime: 2025-12-29 11:51:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/renagel.html
document_name: renagel.html
version: success
processing_time: 0.1148165
conversion_datetime: 2025-12-30 00:28:41.155596
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Renagel

[RSS](/en/individual-human-medicine.xml/65559)

##### Authorised

This medicine is authorised for use in the European Union

sevelamer Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Renagel?

Renagel is a medicine that contains the active substance sevelamer hydrochloride. It is available as tablets (400 and 800 mg).

## What is Renagel used for?

Renagel is used to control hyperphosphataemia (high blood phosphate levels) in adults on dialysis (a blood clearance technique used in patients with kidney disease). It can be used in patients undergoing haemodialysis (dialysis using a blood filtration machine) or peritoneal dialysis (where fluid is pumped into the abdomen and an internal body membrane filters the blood). Renagel should be used with other treatments such as calcium or vitamin-D supplements to control the development of bone disease.

The medicine can only be obtained with a prescription.

## How is Renagel used?

The recommended starting dose of Renagel depends on the level of phosphate in the blood and ranges from 800 to 1,600 mg three times a day. The dose of Renagel should be adjusted to ensure that the blood phosphate level stays below 1.76 mmol/l. Patients should take Renagel tablets whole with meals and stick to their prescribed diets.

## How does Renagel work?

Patients with long-term kidney disease cannot eliminate phosphate from their bodies. This leads to hyperphosphataemia, which, in the long term, can cause complications such as heart and bone disease. The active substance in Renagel, sevelamer hydrochloride, is a phosphate binder. When taken with meals, it attaches to phosphate from food within the gut, preventing it from being absorbed into the body. This helps to reduce the phosphate levels in the blood.

## How has Renagel been studied?

In haemodialysis, Renagel has been studied in two short-term studies lasting eight weeks and one longer study lasting 44 weeks. The first study compared Renagel with calcium acetate (another phosphate-lowering medicine) in 84 patients. The second, which did not compare Renagel with any other medicines, included 172 patients. The longer study looked at the use of Renagel in 192 patients, the majority of whom had taken Renagel in previous studies.

In peritoneal dialysis, there has been one study comparing Renagel with calcium acetate in 143 patients over 12 weeks.

In all of the studies, the main measure of effectiveness was the change in blood phosphate levels between the start and the end of treatment.

## What benefit has Renagel shown during the studies?

Renagel produced a significant decrease in serum phosphate in all of the studies.

In the comparative study of patients undergoing haemodialysis, there was an average fall of 0.65 mmol/l over the eight weeks of Renagel treatment, compared with 0.68 mmol/l when the patients were taking calcium acetate. Patients taking Renagel had a similar fall in phosphate levels in the second study. In the third, there was an average fall of 0.71 mmol/l over 44 weeks.

In the study of patients undergoing peritoneal dialysis, the patients receiving Renagel had similar falls in phosphate as the patients receiving calcium acetate (0.52 and 0.58 mmol/l, respectively).

## What is the risk associated with Renagel?

The most common side effects with Renagel (seen in more than 1 patient in 10) are nausea (feeling sick) and vomiting. For the full list of all side effects reported with Renagel, see the package leaflet.

Renagel must not be used in people with hypophosphataemia (low blood phosphate levels) or with bowel obstruction (a blockage in the gut).

## Why has Renagel been approved?

The CHMP decided that Renagel's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Renagel?

A risk management plan has been developed to ensure that Renagel is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Renagel, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Renagel

The European Commission granted a marketing authorisation valid throughout the European Union for Renagel on 28 January 2000.

The full EPAR for Renagel can be found on the Agency's website.

For more information about treatment with Renagel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Renagel : EPAR - Summary for the public

English (EN) (74.31 KB - PDF)

**First published:** 21/07/2008

**Last updated:** 13/07/2015

[View](/en/documents/overview/renagel-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-496)

български (BG) (100.11 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/bg/documents/overview/renagel-epar-summary-public_bg.pdf)

español (ES) (74.73 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/es/documents/overview/renagel-epar-summary-public_es.pdf)

čeština (CS) (98.77 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/cs/documents/overview/renagel-epar-summary-public_cs.pdf)

dansk (DA) (74.15 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/da/documents/overview/renagel-epar-summary-public_da.pdf)

Deutsch (DE) (75.54 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/de/documents/overview/renagel-epar-summary-public_de.pdf)

eesti keel (ET) (73.85 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/et/documents/overview/renagel-epar-summary-public_et.pdf)

ελληνικά (EL) (102.55 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/el/documents/overview/renagel-epar-summary-public_el.pdf)

français (FR) (75.4 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/fr/documents/overview/renagel-epar-summary-public_fr.pdf)

hrvatski (HR) (94.05 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/hr/documents/overview/renagel-epar-summary-public_hr.pdf)

italiano (IT) (74.35 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/it/documents/overview/renagel-epar-summary-public_it.pdf)

latviešu valoda (LV) (96.6 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/lv/documents/overview/renagel-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (97.11 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/lt/documents/overview/renagel-epar-summary-public_lt.pdf)

magyar (HU) (92.75 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/hu/documents/overview/renagel-epar-summary-public_hu.pdf)

Malti (MT) (100.19 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/mt/documents/overview/renagel-epar-summary-public_mt.pdf)

Nederlands (NL) (74.79 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/nl/documents/overview/renagel-epar-summary-public_nl.pdf)

polski (PL) (99.18 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/pl/documents/overview/renagel-epar-summary-public_pl.pdf)

português (PT) (75.05 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/pt/documents/overview/renagel-epar-summary-public_pt.pdf)

română (RO) (95.43 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/ro/documents/overview/renagel-epar-summary-public_ro.pdf)

slovenčina (SK) (98.59 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/sk/documents/overview/renagel-epar-summary-public_sk.pdf)

slovenščina (SL) (91.41 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/sl/documents/overview/renagel-epar-summary-public_sl.pdf)

Suomi (FI) (74.13 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/fi/documents/overview/renagel-epar-summary-public_fi.pdf)

svenska (SV) (73.85 KB - PDF)

**First published:**

21/07/2008

**Last updated:**

13/07/2015

[View](/sv/documents/overview/renagel-epar-summary-public_sv.pdf)

## Product information

Renagel : EPAR - Product Information

English (EN) (493.46 KB - PDF)

**First published:** 04/09/2009

**Last updated:** 22/01/2025

[View](/en/documents/product-information/renagel-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-662)

български (BG) (453.98 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/bg/documents/product-information/renagel-epar-product-information_bg.pdf)

español (ES) (452.23 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/es/documents/product-information/renagel-epar-product-information_es.pdf)

čeština (CS) (421.45 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/cs/documents/product-information/renagel-epar-product-information_cs.pdf)

dansk (DA) (341.24 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/da/documents/product-information/renagel-epar-product-information_da.pdf)

Deutsch (DE) (470.09 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/de/documents/product-information/renagel-epar-product-information_de.pdf)

eesti keel (ET) (419.07 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/et/documents/product-information/renagel-epar-product-information_et.pdf)

ελληνικά (EL) (565.86 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/el/documents/product-information/renagel-epar-product-information_el.pdf)

français (FR) (404.8 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/fr/documents/product-information/renagel-epar-product-information_fr.pdf)

hrvatski (HR) (363.28 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/hr/documents/product-information/renagel-epar-product-information_hr.pdf)

íslenska (IS) (339.49 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/is/documents/product-information/renagel-epar-product-information_is.pdf)

italiano (IT) (495.24 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/it/documents/product-information/renagel-epar-product-information_it.pdf)

latviešu valoda (LV) (432.76 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/lv/documents/product-information/renagel-epar-product-information_lv.pdf)

lietuvių kalba (LT) (424.3 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/lt/documents/product-information/renagel-epar-product-information_lt.pdf)

magyar (HU) (595.36 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/hu/documents/product-information/renagel-epar-product-information_hu.pdf)

Malti (MT) (610.13 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/mt/documents/product-information/renagel-epar-product-information_mt.pdf)

Nederlands (NL) (320.39 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/nl/documents/product-information/renagel-epar-product-information_nl.pdf)

norsk (NO) (465.74 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/no/documents/product-information/renagel-epar-product-information_no.pdf)

polski (PL) (439.65 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/pl/documents/product-information/renagel-epar-product-information_pl.pdf)

português (PT) (460.5 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/pt/documents/product-information/renagel-epar-product-information_pt.pdf)

română (RO) (514.99 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/ro/documents/product-information/renagel-epar-product-information_ro.pdf)

slovenčina (SK) (410.52 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/sk/documents/product-information/renagel-epar-product-information_sk.pdf)

slovenščina (SL) (393.38 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/sl/documents/product-information/renagel-epar-product-information_sl.pdf)

Suomi (FI) (495.24 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/fi/documents/product-information/renagel-epar-product-information_fi.pdf)

svenska (SV) (439.49 KB - PDF)

**First published:**

04/09/2009

**Last updated:**

22/01/2025

[View](/sv/documents/product-information/renagel-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0123 13/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Renagel : EPAR - All Authorised presentations

English (EN) (26.31 KB - PDF)

**First published:** 04/09/2008

**Last updated:** 04/09/2008

[View](/en/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-77)

български (BG) (97.64 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/bg/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.79 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/es/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_es.pdf)

čeština (CS) (96.83 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/cs/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.33 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/da/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.59 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/de/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (29.7 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/et/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (92.56 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/el/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_el.pdf)

français (FR) (26.53 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/fr/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (29.02 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/it/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (97.03 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/lv/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (95.65 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/lt/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (95.65 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/hu/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (95.01 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/mt/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (29.13 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/nl/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_nl.pdf)

polski (PL) (98.34 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/pl/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.42 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/pt/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_pt.pdf)

română (RO) (90.8 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/ro/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (93.84 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/sk/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (58.03 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/sl/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (26.95 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/fi/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.54 KB - PDF)

**First published:**

04/09/2008

**Last updated:**

04/09/2008

[View](/sv/documents/all-authorised-presentations/renagel-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Renagel Active substance sevelamer International non-proprietary name (INN) or common name sevelamer Therapeutic area (MeSH)

- Renal Dialysis
- Hyperphosphatemia

Anatomical therapeutic chemical (ATC) code V03AE02

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis.

Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.

## Authorisation details

EMA product number EMEA/H/C/000254 Marketing authorisation holder

Sanofi B.V.

Paasheuvelweg 25

Opinion adopted 23/09/1999 Marketing authorisation issued 28/01/2000 Revision 38

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Renagel : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (273.19 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 22/01/2025

[View](/en/documents/procedural-steps-after/renagel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Renagel-H-C-PSUSA-00002697-201810 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/462037/2019

English (EN) (68.1 KB - PDF)

**First published:** 03/09/2019

[View](/en/documents/scientific-conclusion/renagel-h-c-psusa-00002697-201810-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Renagel-H-C-PSUSA-00002697-201510 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/571186/2016

English (EN) (74.06 KB - PDF)

**First published:** 02/09/2016

**Last updated:** 02/09/2016

[View](/en/documents/scientific-conclusion/renagel-h-c-psusa-00002697-201510-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Renagel-H-C-254-PSUV-0101: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/768723/2014

English (EN) (76.12 KB - PDF)

**First published:** 12/03/2015

**Last updated:** 12/03/2015

[View](/en/documents/scientific-conclusion/renagel-h-c-254-psuv-0101-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Renagel-H-C-254-II-0056 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (114.62 KB - PDF)

**First published:** 14/06/2007

**Last updated:** 14/06/2007

[View](/en/documents/scientific-discussion-variation/renagel-h-c-254-ii-0056-epar-scientific-discussion-variation_en.pdf)

Renagel : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (91.32 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/renagel-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Renagel : EPAR - Scientific Discussion

English (EN) (196.32 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/renagel-epar-scientific-discussion_en.pdf)

Renagel : EPAR - Procedural steps taken before authorisation

English (EN) (100.73 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/renagel-epar-procedural-steps-taken-authorisation_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 22/01/2025

## Share this page

[Back to top](#main-content)